ESR1 and breast carcinoma: Given the relative abundance of AR-V7 transcripts compared to other AR splice variants in the TCGA dataset, we validated its expression in an independent cohort of prospectively collected primary breast cancers (n = 54), comprised of the expected proportion of ERα-positive (64.8%) and ERα-negative (35.2%) cases (Supplementary Table S2).